Publication date: Jul 12, 2024
The aim of this analysis was to assess glycemic control before and during the coronavirus disease (COVID-19) pandemic. Data from 64 (main analysis) and 80 (sensitivity analysis) people with type 1 diabetes (T1D) using intermittently scanned continuous glucose monitoring (isCGM) were investigated retrospectively. The baseline characteristics were collected from electronic medical records. The data were examined over three periods of three months each: from 16th of March 2019 until 16th of June 2019 (pre-pandemic), from 1st of December 2019 until 29th of February 2020 (pre-lockdown) and from 16th of March 2020 until 16th of June 2020 (lockdown 2020), representing the very beginning of the COVID-19 pandemic and the first Austrian-wide lockdown. For the main analysis, 64 individuals with T1D (22 female, 42 male), who had a mean glycated hemoglobin (HbA1c) of 58. 5 mmol/mol (51. 0 to 69. 3 mmol/mol) and a mean diabetes duration 13. 5 years (5. 5 to 22. 0 years) were included in the analysis. The time in range (TIR) was the highest percentage of measures within all three studied phases, but the lockdown 2020 phase delivered the best data in all these cases. Concerning the time below range (TBR) and the time above range (TAR), the lockdown 2020 phase also had the best values. Regarding the sensitivity analysis, 80 individuals with T1D (26 female, 54 male), who had a mean HbA1c of 57. 5 mmol/mol (51. 0 to 69. 3 mmol/mol) and a mean diabetes duration of 12. 5 years (5. 5 to 20. 7 years), were included. The TIR was also the highest percentage of measures within all three studied phases, with the lockdown 2020 phase also delivering the best data in all these cases. The TBR and the TAR underscored the data in the main analysis. Superior glycemic control, based on all parameters analyzed, was achieved during the first Austrian-wide lockdown compared to prior periods, which might be a result of reduced daily exertion or more time spent focusing on glycemic management.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Dextrose unspecified form |
| disease | MESH | Type 1 Diabetes |
| disease | MESH | COVID-19 Pandemic |
| pathway | KEGG | Coronavirus disease |
| disease | VO | time |
| disease | VO | Tir |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | Metabolic Diseases |
| disease | IDO | blood |
| disease | MESH | diabetes mellitus |
| disease | MESH | complications |
| disease | VO | organ |